Incannex (ASX: IHL) partners with Procaps to develop cannabis medicine for clinical trial on sleep apnea
Cannabis Law Report
OCTOBER 26, 2021
The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. If these trials are successful and IHL-42X is approved for the market, Procaps will also make IHL-42X for patients.
Let's personalize your content